Meftal%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520spas

# Meftal Spas ## Overview Meftal Spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine, an anticholinergic/antispasmodic agent. ## Primary Indications * Symptomatic relief of mild to moderate pain associated with smooth muscle spasms. * Commonly used for abdominal pain, menstrual cramps, and other spasmodic conditions. ## Adult Dosing * **Mefenamic Acid Component:** Typically 250 mg to 500 mg orally every 6 to 8 hours as needed. Maximum daily dose of mefenamic acid is generally 1500 mg. * **Dicyclomine Component:** Typically 10 mg to 20 mg orally four times daily as needed. Maximum daily dose of dicyclomine is generally 80 mg. * **Combination Product:** Specific dosing for Meftal Spas will depend on the concentration of each active ingredient in the available formulation. Follow product labeling or local protocol. ## Pediatric Dosing * **Mefenamic Acid:** Not typically recommended for children under 14 years of age due to potential for adverse effects. If used, dosing is generally weight-based, but exact pediatric guidelines are less established and should be determined by a specialist. * **Dicyclomine:** Dosing in children is generally not recommended, especially in infants, due to the risk of serious adverse effects including respiratory depression, coma, and circulatory collapse. If used, it should be under strict medical supervision and with caution. * **Combination Product:** Meftal Spas is generally not recommended for pediatric use. ## Dose Adjustments * **Renal Impairment:** Mefenamic acid should be used with caution in patients with impaired renal function. Dose reduction may be necessary. * **Hepatic Impairment:** Mefenamic acid should be used with caution in patients with impaired hepatic function. * **Elderly:** Elderly patients may be more susceptible to the adverse effects of NSAIDs, including gastrointestinal bleeding and renal toxicity. Use with caution and at the lowest effective dose. ## Contraindications * Known hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs. * History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. * Inflammatory bowel disease. * Glaucoma. * Myasthenia gravis. * Obstructive uropathy or gastrointestinal obstruction. * Unstable cardiac conditions. * Severe renal or hepatic impairment. * Use in patients with significant cardiovascular disease or risk factors for cardiovascular disease (for mefenamic acid component). ## Adverse Effects * **Common (Mefenamic Acid):** Nausea, vomiting, diarrhea, abdominal pain, dyspepsia, dizziness, drowsiness. * **Serious (Mefenamic Acid):** Gastrointestinal bleeding, ulceration, perforation; renal toxicity; hepatic toxicity; cardiovascular thrombotic events; hypersensitivity reactions; Stevens-Johnson syndrome/toxic epidermal necrolysis. * **Common (Dicyclomine):** Dry mouth, blurred vision, constipation, urinary retention, drowsiness, dizziness. * **Serious (Dicyclomine):** Confusion, hallucinations, tachycardia, difficulty breathing, severe allergic reactions. ## Key Drug Interactions * **Mefenamic Acid:** * **Anticoagulants (e.g., warfarin):** Increased risk of bleeding. * **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding. * **Other NSAIDs/Aspirin:** Increased risk of gastrointestinal toxicity and bleeding. * **Diuretics/ACE inhibitors/ARBs:** May reduce antihypertensive effect and increase risk of renal toxicity. * **Lithium/Methotrexate:** Increased serum levels and potential for toxicity. * **Dicyclomine:** * **Other Anticholinergics:** Additive anticholinergic effects. * **MAO Inhibitors:** May potentiate anticholinergic effects. * **Amanatdine:** Additive anticholinergic effects. ## Monitoring * **Renal function:** Baseline and periodic monitoring, especially in patients with risk factors. * **Hepatic function:** Baseline and periodic monitoring, especially in patients with risk factors. * **Gastrointestinal symptoms:** Assess for signs of bleeding or ulceration. * **Cardiovascular risk factors:** Evaluate and monitor for NSAID-associated cardiovascular events. * **Signs of anticholinergic toxicity:** Monitor for dry mouth, blurred vision, urinary retention, constipation, and cognitive changes. ## Clinical Pearls * Meftal Spas should be used at the lowest effective dose for the shortest duration necessary to minimize risks. * Concomitant use with alcohol should be avoided due to increased risk of gastrointestinal irritation and bleeding. * Patients should be advised to report any signs of gastrointestinal bleeding (e.g., black tarry stools, vomiting blood) or other serious adverse effects immediately. * The anticholinergic effects of dicyclomine can be more pronounced in elderly patients. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Local protocols may vary.